Sara Labiano
YOU?
Author Swipe
View article: P06.11.A CONVENTIONAL TYPE 1 DENDRITIC CELLS ENHANCE NEUROPROTECTION IN PEDIATRIC BRAIN TUMOR RADIOTHERAPY
P06.11.A CONVENTIONAL TYPE 1 DENDRITIC CELLS ENHANCE NEUROPROTECTION IN PEDIATRIC BRAIN TUMOR RADIOTHERAPY Open
BACKGROUND As of today, many of the pediatric brain tumor treatment regimens include radiotherapy (RT). Despite protocol improvements, brain irradiation leads to adverse effects on cognitive function, such as problems with learning, memory…
View article: Targeting the CD40 costimulatory receptor to improve virotherapy efficacy in diffuse midline gliomas
Targeting the CD40 costimulatory receptor to improve virotherapy efficacy in diffuse midline gliomas Open
Diffuse midline glioma (DMG) is a devastating pediatric brain tumor. The oncolytic adenovirus Delta-24-RGD has shown promising efficacy and safety in DMG patients but is not yet curative. Thus, we hypothesized that activating dendritic cel…
View article: PD-1 cis-targeted IL-2v in combination with radiotherapy inhibits lung cancer growth and remodels the immune microenvironment
PD-1 cis-targeted IL-2v in combination with radiotherapy inhibits lung cancer growth and remodels the immune microenvironment Open
Background More efficient therapeutic options for non-small cell lung cancer (NSCLC) are needed as the survival at 5 years of metastatic disease is near zero. In this regard, we used a preclinical model of metastatic lung adenocarcinoma (S…
View article: 996 Modulating tumor metabolism to overcome mechanisms of resistance to viroimmunotherapy in pediatric brain tumors
996 Modulating tumor metabolism to overcome mechanisms of resistance to viroimmunotherapy in pediatric brain tumors Open
View article: Combination of locoregional radiotherapy with a TIM-3 aptamer improves survival in diffuse midline glioma models
Combination of locoregional radiotherapy with a TIM-3 aptamer improves survival in diffuse midline glioma models Open
Pediatric diffuse midline gliomas (DMG) with altered H3-K27M are aggressive brain tumors that arise during childhood. Despite advances in genomic knowledge and the significant number of clinical trials testing new targeted therapies, patie…
View article: The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models
The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models Open
Background Pediatric high-grade gliomas (pHGGs), including diffuse midline gliomas (DMGs), are aggressive pediatric tumors with one of the poorest prognoses. Delta-24-RGD and ONC201 have shown promising efficacy as single agents for these …
View article: Characterization of immune populations in the tumor microenvironment of diffuse midline glioma orthotopic mouse models by flow cytometry
Characterization of immune populations in the tumor microenvironment of diffuse midline glioma orthotopic mouse models by flow cytometry Open
View article: 863 Novel radioimmunotherapy for lung cancer: a tumor targeting approach
863 Novel radioimmunotherapy for lung cancer: a tumor targeting approach Open
Background Novel efficient therapeutic options for lung carcinoma are needed as the survival at 5 years of metastatic disease treated by the standard of care is near zero. Methods In this regard, we used a novel preclinical model of lung a…
View article: TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory
TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory Open
Diffuse intrinsic pontine glioma (DIPG) is an aggressive brain stem tumor and the leading cause of pediatric cancer-related death. To date, these tumors remain incurable, underscoring the need for efficacious therapies. In this study, we d…
View article: P17.14.B PHASE I TRIAL OF DNX-2401 ONCOLYTIC ADENOVIRUS COMBINED WITH A SHORT COURSE OF DOSE-DENSE TEMOZOLOMIDE FOR RECURRENT GLIOBLASTOMA
P17.14.B PHASE I TRIAL OF DNX-2401 ONCOLYTIC ADENOVIRUS COMBINED WITH A SHORT COURSE OF DOSE-DENSE TEMOZOLOMIDE FOR RECURRENT GLIOBLASTOMA Open
BACKGROUND Oncolytic virotherapy is emerging as a novel therapeutic strategy for glioblastoma (GBM). DNX-2401, an oncolytic adenovirus with selective replication and enhanced infectivity in tumor cells, showed anti-tumor effect in a previo…
View article: P17.15.A THANK PHASE I TRIAL OF DNX-2440 ONCOLYTIC ADENOVIRUS IN PATIENTS WITH FIRST OR SECOND RECURRENCE OF GLIOBLASTOMA: PRELIMINARY RESULTS
P17.15.A THANK PHASE I TRIAL OF DNX-2440 ONCOLYTIC ADENOVIRUS IN PATIENTS WITH FIRST OR SECOND RECURRENCE OF GLIOBLASTOMA: PRELIMINARY RESULTS Open
BACKGROUND Oncolytic immunovirotherapy is emerging as a potential therapeutic approach in neuro-oncology. The oncolytic adenovirus DNX-2401, genetically engineered for selective replication and enhanced infectivity in tumor cells, has show…
View article: Supplementary Table 3 from CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8<sup>+</sup> T Cell–Relevant Genes
Supplementary Table 3 from CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8<sup>+</sup> T Cell–Relevant Genes Open
Primer sequences
View article: Supplementary Figure from Local Treatment of a Pediatric Osteosarcoma Model with a 4-1BBL Armed Oncolytic Adenovirus Results in an Antitumor Effect and Leads to Immune Memory
Supplementary Figure from Local Treatment of a Pediatric Osteosarcoma Model with a 4-1BBL Armed Oncolytic Adenovirus Results in an Antitumor Effect and Leads to Immune Memory Open
Supplementary Figure from Local Treatment of a Pediatric Osteosarcoma Model with a 4-1BBL Armed Oncolytic Adenovirus Results in an Antitumor Effect and Leads to Immune Memory
View article: Supplementary Table 1 from CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8<sup>+</sup> T Cell–Relevant Genes
Supplementary Table 1 from CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8<sup>+</sup> T Cell–Relevant Genes Open
DNA methylation array results with urelumab
View article: Supplementary Figure Legends from Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti–PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells
Supplementary Figure Legends from Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti–PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells Open
Supplementary Figure Legends
View article: Supplementary Figure from Local Treatment of a Pediatric Osteosarcoma Model with a 4-1BBL Armed Oncolytic Adenovirus Results in an Antitumor Effect and Leads to Immune Memory
Supplementary Figure from Local Treatment of a Pediatric Osteosarcoma Model with a 4-1BBL Armed Oncolytic Adenovirus Results in an Antitumor Effect and Leads to Immune Memory Open
Supplementary Figure from Local Treatment of a Pediatric Osteosarcoma Model with a 4-1BBL Armed Oncolytic Adenovirus Results in an Antitumor Effect and Leads to Immune Memory
View article: Supplemental Figures 1-10 from Mitochondrial Morphological and Functional Reprogramming Following CD137 (4-1BB) Costimulation
Supplemental Figures 1-10 from Mitochondrial Morphological and Functional Reprogramming Following CD137 (4-1BB) Costimulation Open
Figure S1 shows that CD8 T cells with high mitochondrial transmembrane potential after CD137 stimulation have enlarged mitochondria. Fig S2 shows that CD137 induced mitochondrial changes are not due to enrichment of specific CD8 T cells su…
View article: Supplementary Figure 3 from Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti–PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells
Supplementary Figure 3 from Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti–PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells Open
Systemic sFlt3L and local intratumoral poly-ICLC expand and mature DCs in B16-OVA bearing mice.
View article: Supplementary Figure 4 from Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti–PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells
Supplementary Figure 4 from Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti–PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells Open
Combinations of immunomodulatory anti-CD137 and anti-PD-1 mAbs synergize with sFlt3L and poly-ICLC against grafted B16F10 and B16-OVA melanomas.
View article: Supplementary Figure Legends from Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti–PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells
Supplementary Figure Legends from Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti–PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells Open
Supplementary Figure Legends
View article: Data from Virotherapy with a Semliki Forest Virus–Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade
Data from Virotherapy with a Semliki Forest Virus–Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade Open
Virotherapy and checkpoint inhibitors can be combined for the treatment of cancer with complementarity and potential for synergistic effects. We have developed a cytolytic but nonreplicative viral vector system based on Semliki Forest viru…
View article: Supplementary Figure 2 from Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti–PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells
Supplementary Figure 2 from Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti–PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells Open
CTLs against the Adpgk neoantigen of MC38 are induced by anti-CD137 and anti-PD-1 mAbs in a fraction of WT mice, but not in Batf3-/- mice.
View article: Data from Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti–PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells
Data from Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti–PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells Open
Weak and ineffective antitumor cytotoxic T lymphocyte (CTL) responses can be rescued by immunomodulatory mAbs targeting PD-1 or CD137. Using Batf3−/− mice, which are defective for cross-presentation of cell-associated ant…
View article: Supplementary Figure 1 from Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti–PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells
Supplementary Figure 1 from Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti–PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells Open
Migratory CD103+ DCs are the main mediators of cross-priming at the tumor-draining LNs.
View article: supplementary figure 1 from CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8<sup>+</sup> T Cell–Relevant Genes
supplementary figure 1 from CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8<sup>+</sup> T Cell–Relevant Genes Open
No change in memory naive proportions and their DNA methylation in relevant genes
View article: Data from Mitochondrial Morphological and Functional Reprogramming Following CD137 (4-1BB) Costimulation
Data from Mitochondrial Morphological and Functional Reprogramming Following CD137 (4-1BB) Costimulation Open
T and NK lymphocytes express CD137 (4-1BB), a costimulatory receptor of the TNFR family whose function is exploitable for cancer immunotherapy. Mitochondria regulate the function and survival of T lymphocytes. Herein, we show that CD137 co…
View article: Supplementary Table 2 from CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8<sup>+</sup> T Cell–Relevant Genes
Supplementary Table 2 from CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8<sup>+</sup> T Cell–Relevant Genes Open
DNA methylation array results with 6B4 antiCD137 mAb
View article: supplementary figure 1 from CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8<sup>+</sup> T Cell–Relevant Genes
supplementary figure 1 from CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8<sup>+</sup> T Cell–Relevant Genes Open
No change in memory naive proportions and their DNA methylation in relevant genes
View article: Supplementary Table 1 from CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8<sup>+</sup> T Cell–Relevant Genes
Supplementary Table 1 from CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8<sup>+</sup> T Cell–Relevant Genes Open
DNA methylation array results with urelumab
View article: Supplementary Figure 1 from Virotherapy with a Semliki Forest Virus–Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade
Supplementary Figure 1 from Virotherapy with a Semliki Forest Virus–Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade Open
Supplementary figure 1. Similar survival results with anti-PD-1 or anti-PD-L1 in the combination with SFV-IL12 for B16-OVA-derived tumors.